The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | Exciting research in AML and important considerations for the future
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, discusses exciting research in the field of acute myeloid leukemia (AML), emphasizing the importance of conducting more studies to compare haploidentical transplantation with other types of transplantation. Prof. Nagler also explains how the introduction of novel agents, such as venetoclax, anti-CD123 monoclonal antibodies (mAbs), and FLT3 inhibitors, have revolutionized the AML treatment landscape, and the need for more data in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
